The objectives were: (1) To demonstrate the efficacy of adalimumab in the long-term
maintenance of clinical remission in participants with Crohn's disease; and (2) To delineate
the long-term safety of adalimumab when administered to participants with Crohn's disease.
Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 152 (Through 2 Years of Participation in NCT01070303).Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 212 (Through 3 Years of Participation in NCT01070303).
Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 260 (4 Years of Participation in NCT01070303).
Number of Participants Achieving CR-100 at Week 104 (1 Year of Participation in NCT01070303)
Number of Participants Achieving CR-100 at Week 152 (2 Years of Participation in NCT01070303)
Number of Participants Achieving CR-100 at Week 212 (3 Years of Participation in NCT01070303)
Number of Participants Achieving CR-100 at Week 260 (4 Years of Participation in NCT01070303)
Number of Participants Achieving CR-70 at Week 104 (1 Year of Participation in NCT01070303)
Number of Participants Achieving CR-70 at Week 152 (2 Years of Participation in NCT01070303)
Number of Participants Achieving CR-70 at Week 212 (3 Years of Participation in NCT01070303)
Number of Participants Achieving CR-70 at Week 260 (4 Years of Participation in NCT01070303)
Number of Participants Achieving Steroid-free Clinical Remission at Week 104 (1 Year of Participation in NCT01070303)
Number of Achieving Steroid-free Clinical Remission at Week 152 (2 Years of Participation in NCT01070303)
Number of Participants Achieving Steroid-free Clinical Remission at Week 212 (3 Years of Participation in NCT01070303)
Number of Participants Achieving Steroid-free Clinical Remission at Week 260 (4 Years of Participation in NCT01070303)
Number of Participants Achieving Steroid-free CR-100 at Week 104 (1 Year of Participation in NCT01070303)
Number of Participants Achieving Steroid-free CR-100 at Week 152 (2 Years of Participation in NCT01070303)
Number of Participants Achieving Steroid-free CR-100 at Week 212 (3 Years of Participation in NCT01070303)
Number of Participants Achieving Steroid-free CR-100 at Week 260 (4 Years of Participation in NCT01070303)
Changes in Inflammatory Bowel Disease Questionnaire (IBDQ) Scores
Number of Participants Achieving Fistula Remission at Week 104 (1 Year of Participation in NCT01070303)
Number of Participants Achieving Fistula Remission at Week 152 (2 Years of Participation in NCT01070303)
Number of Participants Achieving Fistula Remission at Week 212 (3 Years of Participation in NCT01070303)
Number of Participants Achieving Fistula Remission at Week 260 (Years of Participation in NCT01070303)
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Gastroenterology Associates of the East Bay, Berkeley, California 94705, United States
Long Beach Gastroenterology Assoc., Long Beach, California 90806, United States
Sharp Rees-Stealy Medical Group, San Diego, California 92123, United States
Gastroenterology Assoc. of Fairfield Co., Bridgeport, Connecticut 06606, United States
Cleveland Clinic Florida, Weston, Florida 33331, United States
Wake Research Associates, Weston, Florida 33331, United States
Shafran Gastroenterology Center, Winter Park, Florida 32789, United States
Atlanta Gastroenterology Assoc., Atlanta, Georgia 30342, United States
Southeastern Digestive & Liver Disease, Savannah, Georgia 31404, United States
Northwest Gastroenterologists, S.C., Arlington Heights, Illinois 60005, United States
University of Chicago, Chicago, Illinois 60637, United States
Drug Research Services, Inc., Metairie, Louisiana 70001, United States
LSU School of Medicine, New Orleans, Louisiana 70115, United States
Digestive Disorders Associates, Annapolis, Maryland 21401, United States
Brigham and Women's Hospital, Boston, Massachusetts 02115, United States
Massachusetts General Hospital, Boston, Massachusetts 02114, United States
Clinical Pharmacology Study Group, Worchester, Massachusetts 01610, United States
Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, United States
Gastroenterology and Hepatology, Kansas City, Missouri 64131, United States
Glenn Gordon, MD, Mexico, Missouri 65265, United States
Deaconess Billings Clinic Research Division, Billings, Montana 59101, United States
Gastroenterology Specialties, P.C., Lincoln, Nebraska 68503, United States
Long Island Clinical Research Associates, Great Neck, New York 11021, United States
NY Center for Clinical Research, Lake Success, New York 11042, United States
Daniel Present, New York, New York 10029, United States
New York Presbyterian Hospital, New York, New York 10021, United States
Rochester Institute for Digestive Diseases, Rochester, New York 14607, United States
UNC School of Medicine, Chapel Hill, North Carolina 27599, United States
Carolina Research Associates, Charlotte, North Carolina 28262, United States
Charlotte Gastroenterology and Hepatology, Charlotte, North Carolina 28207, United States
Digestive Health Specialists, Winston-Salem, North Carolina 27103, United States
Consultants for Clinical Research, Cincinnati, Ohio 45219, United States
Oklahoma Foundation for Digestive Disease, Oklahoma City, Oklahoma 73104, United States
Research Solutions, Tulsa, Oklahoma 74104, United States
Altoona Center for Clinical Research, Duncansville, Pennsylvania 16635, United States
Peter Molloy, MD, Pittsburgh, Pennsylvania 15224, United States
Diseases of the Digestive System, Chattanooga, Tennessee 37421, United States
Nashville Medical Research Institute, Nashville, Tennessee 37205, United States
Charlottesville Medical Research, Charlottesville, Virginia 22902, United States
Northwest Gastroenterology, Bellevue, Washington 98004, United States
Inland Empire Gastroenterology, Spokane, Washington 99204, United States
Tacoma Digestive Disease Center, Tacoma, Washington 98405, United States
Wisconsin Center for Advanced Research, Milwaukee, Wisconsin 53207, United States